Physician
Intermountain Front Range, INC.
Intermountain Front Range, INC. was paid $18.95M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoINTERMOUNTAIN FRONT RANGE, INC.
WHEAT RIDGE, CO 80401
WHEAT RIDGE, CO 80401
33aNPI1669461281assigned 10/17/2005
33bProvider typeMedical Oncology Physician
28Total paid$18.95M
24GClaims635,913
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medical Oncology Physician providers in Colorado
Rank by total paid#1 of 11
Median peer was paid$30K
This provider vs. median623×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,795 | $3.21M | |
| 2019 | 90,916 | $2.67M | |
| 2020 | 87,314 | $2.40M | |
| 2021 | 92,585 | $2.60M | |
| 2022 | 88,472 | $2.73M | |
| 2023 | 99,950 | $2.98M | |
| 2024incomplete | 71,881 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 66,350 | 57,291 | $6.91M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 45,439 | 40,479 | $5.07M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 21,532 | 17,811 | $2.20M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.5% | 47,923 | 40,705 | $847K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 2,891 | 2,461 | $691K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 9,908 | 8,103 | $498K |
| 80320 | 2.1% | 4,214 | 3,293 | $390K | |
| 95811 | 1.9% | 606 | 554 | $364K | |
| J3490 | Unclassified drugs | 1.8% | 133,886 | 68,772 | $335K |
| 80053 | Comprehensive metabolic panel | 1.4% | 27,705 | 22,413 | $259K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 253 | 219 | $147K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 908 | 747 | $139K |
93 more codes
| 95806 | <1% | 432 | $115K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 596 | $110K |
| G0378 | Hospital observation service, per hour | <1% | 739 | $105K |
| 84484 | <1% | 7,443 | $95K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 171 | $92K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 261 | $81K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 993 | $68K |
| 80076 | <1% | 4,458 | $50K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,079 | $47K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,386 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 35,520 | $30K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 477 | $28K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 787 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,214 | $21K |
| 83605 | <1% | 658 | $21K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 509 | $20K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 138 | $18K |
| 80329 | <1% | 343 | $17K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 248 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 47 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,370 | $10K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 190 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 873 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 85 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 53 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,123 | $6K |
| 87631 | <1% | 95 | $6K | |
| 82728 | <1% | 671 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 66 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,532 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 448 | $4K |
| 80061 | Lipid panel | <1% | 567 | $4K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 157 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,311 | $4K |
| 82043 | <1% | 97 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,640 | $2K |
| 81001 | <1% | 7,216 | $2K | |
| 82570 | <1% | 97 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $986.26 |
| 87486 | <1% | 16 | $908.49 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14 | $891.48 |
| 83690 | <1% | 5,801 | $822.91 | |
| 84703 | <1% | 4,893 | $801.90 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16,457 | $783.83 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,909 | $667.82 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 391 | $666.03 |
| 87581 | <1% | 16 | $631.53 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 30 | $624.72 |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 100 | $546.35 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,697 | $344.27 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 231 | $273.70 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,554 | $232.13 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $129.87 |
| 83735 | <1% | 179 | $92.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,140 | $62.41 |
| 83550 | <1% | 44 | $50.80 | |
| 83540 | <1% | 44 | $40.85 | |
| 82607 | <1% | 28 | $22.12 | |
| 82525 | <1% | 30 | $19.28 | |
| 81003 | <1% | 73 | $16.26 | |
| 84630 | <1% | 30 | $9.64 | |
| 84425 | <1% | 30 | $5.34 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 463 | $3.43 |
| 84590 | <1% | 29 | $2.67 | |
| 84100 | <1% | 29 | $2.16 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 610 | $1.98 |
| J2704 | Injection, propofol, 10 mg | <1% | 580 | $0.94 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 75 | $0.03 |
| 96376 | 0% | 176 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 856 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 274 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 303 | $0.00 |
| 85027 | 0% | 325 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 114 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 36 | $0.00 |
| 87081 | 0% | 70 | $0.00 | |
| 94762 | 0% | 48 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 13 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 12 | $0.00 |
| 84145 | 0% | 35 | $0.00 | |
| 82248 | 0% | 329 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 367 | $0.00 |
| 87339 | 0% | 42 | $0.00 | |
| S9443 | Lactation classes, non-physician provider, per session | 0% | 18 | $0.00 |
| S9480 | Intensive outpatient psychiatric services, per diem | 0% | 416 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 84 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 18 | $0.00 |
| 83970 | 0% | 29 | $0.00 | |
| 85610 | 0% | 20 | $0.00 | |
| 82947 | 0% | 38 | $0.00 | |
| 81025 | 0% | 17 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDENTON, ASHLEY (VP OF FINANCE)
Parent organizationINTEGRITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Intermountain Front Range, INC. | Wheat Ridge, CO | $863K |
| Intermountain Front Range, INC. | Wheat Ridge, CO | $113K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.